Overview

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Status:
Completed
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The study also seeks to demonstrate target modulation and early signs of clinical response in select patient populations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
BioMed Valley Discoveries, Inc